loading...| Preferred Name |
miltefosine |
|
| Synonyms |
D-18506 |
|
| Definitions |
An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity. Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1170" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1170" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041212 |
|
| altLabel |
D-18506 Miltefosin Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate hexadecylphosphocholine Miltefosina HDPC Miltefosinum Miltex n-Hexadecylphosphorylcholine 2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt |
|
| CAS Registry |
58066-85-6 |
|
| cui |
C1513304 C0111934 C0068006 |
|
| Date last modified |
2006-12-12 |
|
| definition |
An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity. Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1170" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1170" NCI Thesaurus) |
|
| Legacy PDQ ID |
4285 |
|
| LT |
TRD |
|
| NCI ID |
C1170 |
|
| notation |
CDR0000041212 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
miltefosine |
|
| tui |
T109 T121 |